NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 84 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 3.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $18 | +100.0% | 10,869 | +7.8% | 0.00% | – |
| Q4 2023 | $9 | -81.2% | 10,086 | -77.2% | 0.00% | – |
| Q3 2023 | $48 | -60.7% | 44,286 | -5.7% | 0.00% | – |
| Q2 2023 | $122 | -36.5% | 46,963 | 0.0% | 0.00% | – |
| Q1 2023 | $192 | -5.0% | 46,963 | +16.9% | 0.00% | – |
| Q4 2022 | $202 | -100.0% | 40,187 | +18.4% | 0.00% | – |
| Q3 2022 | $445,000 | +69.8% | 33,945 | +66.1% | 0.00% | – |
| Q2 2022 | $262,000 | -9.7% | 20,440 | +7.5% | 0.00% | – |
| Q1 2022 | $290,000 | -10.2% | 19,015 | +4.4% | 0.00% | – |
| Q4 2021 | $323,000 | -96.0% | 18,220 | -95.3% | 0.00% | -100.0% |
| Q3 2021 | $8,087,000 | -5.5% | 384,716 | -11.3% | 0.00% | 0.0% |
| Q2 2021 | $8,556,000 | -22.4% | 433,858 | +14.3% | 0.00% | 0.0% |
| Q1 2021 | $11,031,000 | – | 379,463 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |